IMAB•benzinga•
I-Mab Announces Approval From China CDE To Initiate Phase 3 Registrational Study Of Lemzoparlimab In Combination With Azacitidine In Higher-Risk Myelodysplastic Syndrome
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 13, 2022 by benzinga